
2016 No. 411 (W. 129)
Water, Wales
The Private Water Supplies (Wales) (Amendment) Regulations 2016  (revoked)
Made 21 March 2016
Laid before the National Assembly for Wales 23 March 2016
Coming into force 14 April 2016
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Title, commencement and interpretation
1 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amendment of regulation 10 (other private supplies)
2 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
New regulations 10A (monitoring of radioactive substances: general) and 10B (monitoring of radioactive substances: supplies to a single dwelling not used for a commercial or public activity)
3 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amendment of Table C (prescribed concentrations, values or states) in Part 2 of Schedule 1
4 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Insertion of new Part 3 (radioactive substances parameters) of Schedule 1
5 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amendment of Part 2 of Schedule 2
6 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Insertion of new Schedule 2A (monitoring of radioactive substances)
7 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Insertion of new Part 3 of Schedule 3 (monitoring for indicative dose and analytical performance characteristics)
8 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

SCHEDULE 1

Regulation 5
“
PART 3 Radioactive substances parameters
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
”
SCHEDULE 2

Regulation 7
“
SCHEDULE 2A
Monitoring of radioactive substances

Regulation 10A
Radon
1 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tritium
2 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Indicative Dose
3 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Water treatment
4 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Averaging
5 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .”
SCHEDULE 3

Regulation 8
“
PART 3 Monitoring for indicative dose and analytical performance characteristics
Monitoring for compliance with the indicative dose
5 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Screening for certain radionuclides, or screening for an individual radionuclide
7 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Screening strategies for gross alpha activity and gross beta activity
9 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Calculation of the indicative dose
12 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Performance characteristics and methods of analysis
14 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .”